Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Meanwhile, Novartis could be looking at another label expansion opportunity with Pluvicto. On Thursday, the company revealed that the phase 3 PSMAddition trial in metastatic hormone-sensitive ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration for commercial manufacturing of Pluvicto TM at its new large-scale, state ...

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility ...

For Novartis, investing in the infrastructure to produce and distribute radiopharmaceuticals would be worthwhile for Pluvicto and Lutathera alone, Bulto said. But it's even more attractive because ...

Novartis received approval from the Food and Drug Administration to produce its Pluvicto radioligand therapy at its new manufacturing facility in Indianapolis, expanding capacity to meet growing ...

Novartis is expanding U.S. production of cancer drug Pluvicto, a build-up that will help the therapy see blockbuster sales. The Swiss drugmaker said Friday it won Food and Drug Administration ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Novartis reports strong Q2 2024 sales, with Kesimpta and Pluvicto showing significant growth. Learn more about NVSEF stock and their expanding product portfolio.

In 2023, Novartis recorded $980 million from Pluvicto sales. Market-moving news hits Benzinga Pro first—get a 30-minute edge and save 60% this 4th of July.

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who ...